Cannabinoid pathways may offer targets for kidney disease as CKD affects 850 million people

Approximately 850 cardinal radical globally (9.1% of the world's population) person chronic kidney illness (CKD). The fig of affected individuals has grown steadily during the past 20 years and is connected way to proceed rising. Existing drugs, specified arsenic RAAS inhibitors and angiotensin receptor blockers, are commonly prescribed, but their effectiveness varies from diligent to patient. Moreover, these drugs tin dilatory illness progression but cannot halt it.